Aspire Biopharma Holdings, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ASBP research report →
Companyaspirebiolabs.com
Aspire Biopharma Holdings, Inc. , an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management.
- CEO
- Kraig T. Higginson
- IPO
- 2025
- Employees
- 2
- HQ
- Estero, FL, US
Price Chart
Valuation
- Market Cap
- $695.69K
- P/E
- -0.08
- P/S
- 20.27
- P/B
- 0.25
- EV/EBITDA
- 0.87
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 16.30%
- Op Margin
- -15745.85%
- Net Margin
- -34040.63%
- ROE
- 199.44%
- ROIC
- -121.89%
Growth & Income
- Revenue
- $6.20K · 0.00%
- Net Income
- $-24,480,848 · -95.27%
- EPS
- $-16.38 · 9.85%
- Op Income
- $-19,351,291
- FCF YoY
- -1756.62%
Performance & Tape
- 52W High
- $35.00
- 52W Low
- $0.11
- 50D MA
- $1.39
- 200D MA
- $7.11
- Beta
- 0.21
- Avg Volume
- 13.50M
Get TickerSpark's AI analysis on ASBP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 5, 25 | Fell Donald G. | buy | 10,500 |
| Jun 4, 25 | Fell Donald G. | buy | 9,500 |
| Jun 5, 25 | Fell Donald G. | buy | 10,500 |
| Jun 4, 25 | Fell Donald G. | buy | 9,500 |
| Aug 18, 23 | AJJARAPU SURENDRA K | other | 0 |
| Aug 18, 23 | AJJARAPU SURENDRA K | other | 6,834,333 |
| Aug 18, 23 | Doshi Mayur Mansukhlal | other | 0 |
| Aug 18, 23 | Wadhwani Avinash R | other | 0 |
| Aug 18, 23 | PETERSON MICHAEL L | other | 0 |
| Aug 18, 23 | Fell Donald G. | other | 0 |
Our ASBP Coverage
We haven't published any research on ASBP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ASBP Report →